- Puma Biotechnology Inc PBYI shares jumped 83.5 percent to $69.35 as briefing documents for Wednesday Advisory Committee meeting are published to the FDA website. The documents showed that neratinib performed better than Roche's trastuzumab in I-SPY2 trial, particularly in subgroup of patients that were HRc negative. The briefing docs also showed that study 3004 met prespecified primary efficacy endpoint.
- Nutraceutical Int'l Corp. NUTR shares surged 49.8 percent to $41.95 after the company agreed to be acquired by HGGC for $41.80 per share in cash.
- Cheetah Mobile Inc (ADR) CMCM shares gained 12.8 percent to $11.90 following strong earnings report.
- Ferroglobe PLC GSM shares surged 12.2 percent to $10.34 after the company posted a narrower-than-expected Q1 loss.
- Nutanix Inc NTNX jumped 11.4 percent to $17.83. Nutanix disclosed the private cloud deployment of SAIC Volkswagen. Goldman Sachs upgraded Nutanix from Neutral to Buy.
- Radius Health Inc RDUS shares climbed 10.4 percent to $38.55 likely on the heels of concerning adverse side effect data from Amgen on its osteoporosis treatment.
- Oclaro, Inc. OCLR shares gained 9 percent to $9.26.
- Yirendai Ltd - ADR YRD shares rose 7.4 percent to $25.78 following Q1 earnings report.
- Blackstone Group LP BX climbed 5.3 percent to $31.45. Citigroup upgraded Blackstone Group from Neutral to Buy.
- Cree, Inc. CREE rose 5.2 percent to $24.30. JMP Securities upgraded Cree from Market Perform to Market Outperform.
- GNC Holdings Inc GNC shares gained 4.7 percent to $7.62 following announcement of Nutraceutical acquisition.
- Booz Allen Hamilton Holding Corporation BAH climbed 4.5 percent to $37.56 as the company posted better-than-expected results for its fourth quarter.
- Ciena Corporation CIEN shares rose 4.1 percent to $23.89. Stifel Nicolaus upgraded Ciena from Hold to Buy.
- Genesco Inc. GCO shares surged 3.4 percent to $46.60. B. Riley upgraded Genesco Inc from Neutral to Buy.
- Carvana Co CVNA rose 3.3 percent to $11.77. Craig-Hallum initiated coverage on Carvana with a Buy rating.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in